Fekra Therapeutics

Fekra Therapeutics

Edit info

  • Founded: 2020
  • Location: Boston, MA
  • Employee range: 1 - 10
  • Clinical stage: Castration-resistant prostate cancer
  • Therapy area: FT-02 RD solid tumors; FT-03 RD non-solid tumors; FT-04 RD inflammatory
  • Drug types: ONC, IMM
  • Lead product: FT-01


fekratx.com

linkedin.com


About:

Fekra Therapeutics is developing new therapeutics to treat cancer. Using their small molecule platform, Curiositome, Fekra is exploring the cell to find cure to patients with devastating diseases. Fekra’s lead program, FT-01, targets the cytoplasmic tyrosine kinase, BMX, for castration-resistant prostate cancer. To design their BMX inhibitor, Fekra used structure-based design and are building a pipeline of projects to also find therapies for solid tumors and non-solid tumors.

Jobs:

Post a job


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com